VAP诊疗研究进展

瞬间后的璀璨

      呼吸机相关肺炎（VAP）是最常见的致死性院内感染之一，但其临床诊断相当困难。一项涉及73例临床可疑VAP患者的研究提示，VAP患者肺泡灌洗液（BALF）的IL-1β和IL-8水平显著升高，并且能够在可疑患者中准确判定VAP[Thorax 2010, 65（3）：201]。另一项研究表明，经口腔或肠道给予乳酸菌等益生菌可在重症患者中安全有效地预防VAP。[Am J Respir Crit Car 2010，182（8）：1058]。





上一篇:请问：老年女性，因股骨颈骨折入院，入院后1个月出现心衰及肺炎，算医院感染吗下一篇:康威达复方次氯酸钠消毒液打开后的有效期是多少天？





[h2]评分[/h2]





参与人数 1 +3
金币 +3

收起
理由





蓝鱼o_0
+ 3
+ 3
赞一个!




查看全部评分

江南水韵

望能看到全文内容，进一步了解研究成果。

xupeijun0818

苏省icu目标性监测的诊断标准很简单，但医生说要下诊断很男，两者矛盾，不知咋办？

sebastienkitty

到前一篇的原文
Abstract
Background Ventilator-associated pneumonia (VAP) is the most commonly fatal nosocomial infection. Clinical diagnosis of VAP remains notoriously inaccurate. The hypothesis was tested that significantly augmented inflammatory markers distinguish VAP from conditions closely mimicking VAP.
Methods A prospective, observational cohort study was carried out in two university hospital intensive care units recruiting 73 patients with clinically suspected VAP, and a semi-urban primary care practice recruiting a reference group of 21 age- and sex-matched volunteers.
Growth of pathogens at >104 colony-forming units (cfu)/ml of bronchoalveolar lavage fluid (BALF) distinguished VAP from “non-VAP”. Inflammatory mediators were quantified in BALF and serum. Mediators showing significant differences between patients with and without VAP were analysed for diagnostic utility by receiver operator characteristic (ROC) curves.
Results Seventy-two patients had recoverable lavage—24% had VAP. BALF interleukin-1β (IL-1β), IL-8, granulocyte colony-stimulating factor and macrophage inflammatory protein-1α were significantly higher in the VAP group (all p

fd_daisy

一篇原文
Probiotic Prophylaxis of Ventilator-associated Pneumonia
A Blinded, Randomized, Controlled Trial
Lee E. Morrow1, Marin H. Kollef2 and Thomas B. Casale3
Abstract
Rationale: Enteral administration of probiotics may modify the gastrointestinal environment in a manner that preferentially favors the growth of minimally virulent species. It is unknown whether probiotic modification of the upper aerodigestive flora can reduce nosocomial infections.
Objectives: To determine whether oropharyngeal and gastric administration of Lactobacillus rhamnosus GG can reduce the incidence of ventilator-associated pneumonia (VAP).
Methods: We performed a prospective, randomized, double-blind, placebo-controlled trial of 146 mechanically ventilated patients at high risk of developing VAP. Patients were randomly assigned to receive enteral probiotics (n = 68) or an inert inulin-based placebo (n = 70) twice a day in addition to routine care.
Measurements and Main Results: Patients treated with Lactobacillus were significantly less likely to develop microbiologically confirmed VAP compared with patients treated with placebo (40.0 vs. 19.1%; P = 0.007). Although patients treated with probiotics had significantly less Clostridium difficile–associated diarrhea than patients treated with placebo (18.6 vs. 5.8%; P = 0.02), the duration of diarrhea per episode was not different between groups (13.2 ± 7.4 vs. 9.8 ± 4.9 d; P = 0.39). Patients treated with probiotics had fewer days of antibiotics prescribed for VAP (8.6 ± 10.3 vs. 5.6 ± 7.8 d; P = 0.05) and for C. difficile–associated diarrhea (2.1 ± 4.8 SD d vs. 0.5 ± 2.3 d; P = 0.02). No adverse events related to probiotic administration were identified.
Conclusions: These pilot data suggest that L. rhamnosus GG is safe and efficacious in preventing VAP in a select, high-risk ICU population.